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G
lycemic control, a worthwhile goal for people
with diabetes, is limited by the barrier of iatro-
genic hypoglycemia (1). Iatrogenic hypoglyce-
mia 1) causes recurrent morbidity in most
people with type 1 diabetes and many with advanced type
2 diabetes and is sometimes fatal, 2) compromises physi-
ological and behavioral defenses against subsequent fall-
ing plasma glucose concentrations and thus causes a
vicious cycle of recurrent hypoglycemia, and 3) precludes
maintenance of euglycemia over a lifetime of diabetes and
therefore full realization of the vascular beneﬁts of glyce-
mic control. The premise of this “Perspective in Diabetes”
is that insight into the pathophysiology of glucose coun-
terregulation in diabetes leads to understanding of the
frequency and impact of, risk factors for, and prevention
of iatrogenic hypoglycemia.
Partial glycemic control reduces, but does not eliminate,
the development of microvascular complications of diabe-
tes (retinopathy, nephropathy, and neuropathy) in type 1
(2) and type 2 (3,4) diabetes. Extrapolation of the Diabetes
Control and Complications Trial (DCCT) retinopathy data
suggests that long-term maintenance of euglycemia might
eliminate those complications (5). Follow-up of the DCCT
patients seemingly indicates that a period of earlier partial
glycemic control reduces the development of macrovascu-
lar complications in type 1 diabetes (6). Aside from the
metformin subset of the U.K. Prospective Diabetes Study
(4), randomized controlled trials of intensive glycemic
therapy have not documented a cardiovascular mortality
beneﬁt in type 2 diabetes (3,7,8). However, those trials do
not exclude a cardiovascular beneﬁt if glycemic control, or
even partial glycemic control, could be maintained over a
longer period of time. In any event, given its documented
microvascular beneﬁt, maintenance of euglycemia over a
lifetime of diabetes would be in the best interest of people
with diabetes if that could be accomplished safely.
Unfortunately, maintenance of euglycemia over a life-
time of diabetes cannot be accomplished safely with
currently available treatment methods because of the
barrier of hypoglycemia (1). Even if they are effective
initially, medications that should not, and probably do not,
cause hypoglycemia (a biguanide [metformin], thiazo-
lidinediones, -glucosidase inhibitors, glucagon-like pep-
tide-1 receptor agonists, and dipeptidyl dipeptidase-IV
inhibitors) seldom maintain euglycemia in the long-term in
type 2 diabetes. The same is true of insulin secretagogues
(sulfonylureas or glinides), which can cause hypoglycemia
in type 2 diabetes. Therapy with insulin causes hypoglyce-
mia progressively more frequently over time in type 2
diabetes and throughout the course of established type 1
diabetes (1,9). Elimination of iatrogenic hypoglycemia
from the lives of people with diabetes will require new
treatment methods that provide plasma glucose–regulated
insulin replacement or secretion.
Frequency of hypoglycemia. Hypoglycemia is a fact of
life for most people with type 1 diabetes (1). The average
patient has untold numbers of episodes of asymptomatic
hypoglycemia and suffers two episodes of symptomatic
hypoglycemia per week (thousands of such episodes over
a lifetime of diabetes). He or she suffers one or more
episodes of severe, temporarily disabling hypoglycemia,
often with seizure or coma, per year. There is no evidence
that this problem has abated over the decade and a half
since it was highlighted by the report of the DCCT (2) in
1993. For example, in 2007 the U.K. Hypoglycemia Study
Group (9) reported an incidence of severe hypoglycemia
of 110 episodes per 100 patient-years (nearly twice that in
the DCCT) in patients with type 1 diabetes, who were
necessarily treated with insulin, for 5 years and an
incidence of 320 episodes per 100 patient-years in those
with type 1 diabetes for 15 years.
Overall, hypoglycemia is less frequent in type 2 diabetes
(1). However, for pathophysiological reasons that will be
discussed shortly, hypoglycemia becomes progressively
more frequent and limiting to glycemic control later in the
course of type 2 diabetes (1). For example, when the U.K.
Hypoglycemia Study Group (9) contrasted patients with
type 2 diabetes treated with insulin for 2 years with
those treated with insulin for 5 years, they found severe
hypoglycemia prevalences of 7 and 25% and incidences of
10 and 70 episodes per 100 patient-years, respectively. The
corresponding values for mild hypoglycemia were 51 and
64% and 410 and 1,020 episodes per 100 patient-years,
respectively. Thus, while the risk of hypoglycemia is
relatively low in the ﬁrst few years of insulin treatment of
type 2 diabetes (at least with current glycemic goals that
are above the euglycemic range), the risk increases sub-
stantially (approaching that in type 1 diabetes) in ad-
vanced type 2 diabetes.
Although they represent only a small fraction of the total
hypoglycemia experience, estimates of the frequency of
severe hypoglycemia, particularly if determined in pro-
spective, population-based studies, are the most reliable
because they are dramatic events that are more likely to be
reported (by the patient or an associate) (1). The prospec-
tive, population-based data of Donnelly et al. (10) indicate
that the overall incidence of hypoglycemia in insulin-
treated type 2 diabetes is approximately one-third of that
in type 1 diabetes. The incidence of any and of severe
hypoglycemia was 4,300 and 115 episodes per 100 pa-
tient-years, respectively, in type 1 diabetes and 1,600 and
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treated type 2 diabetes. In addition, in population-based
studies the incidence of severe hypoglycemia requiring
emergency treatment in insulin-treated type 2 diabetes
was 40% (11) and 100% (12) of that in type 1 diabetes.
Since the prevalence of type 2 diabetes is 20-fold greater
than that of type 1 diabetes, and most people with type 2
diabetes ultimately require treatment with insulin, these
data suggest that most episodes of iatrogenic hypoglyce-
mia, including severe hypoglycemia, occur in people with
type 2 diabetes.
Impact of hypoglycemia. Iatrogenic hypoglycemia
causes recurrent physical and psychological morbidity and
some mortality, impairs defenses against subsequent hy-
poglycemia, and precludes maintenance of euglycemia
over a lifetime of diabetes (1). Hypoglycemia causes brain
fuel deprivation that, if unchecked, results in functional
brain failure that is typically corrected after the plasma
glucose concentration is raised (13). Rarely, it causes
sudden, presumably cardiac arrhythmic death or, if it is
profound and prolonged, brain death (13). To the extent
that there is a macrovascular beneﬁt of glycemic control
(6), the barrier of hypoglycemia also contributes to car-
diovascular morbidity and mortality.
The physical morbidity of an episode of hypoglycemia
ranges from unpleasant symptoms to seizure and coma
(1). Hypoglycemia can impair judgment, behavior, and
performance of physical tasks. Permanent neurological
damage is rare. While there is concern that recurrent
hypoglycemia might cause chronic cognitive impairment,
long-term follow-up of the DCCT patients is largely reas-
suring in that regard (14). Nonetheless, the possibility that
it might do so in young children or the elderly remains (1).
The psychological morbidity includes fear of hypoglyce-
mia, which can be a barrier to glycemic control (1).
Three early reports indicated that 2–4% of people with
diabetes die from hypoglycemia (1). More recent reports
indicated that 6% (14), 7% (15), and 10% (16) of deaths of
people with type 1 diabetes were the result of hypoglyce-
mia. Up to 10% of episodes of severe sulfonylurea-induced
hypoglycemia in type 2 diabetes may be fatal (17).
In the Action to Control Cardiovascular Risk in Diabetes
(ACCORD) study, 10,251 patients with type 2 diabetes at
high cardiovascular risk (but with no history of frequent or
recent serious hypoglycemic events) were randomized to
either intensive glycemic therapy with an A1C goal of
6.0% or to standard glycemic therapy (7). After a median
follow-up of 3.4 years, with stable median A1C levels of 6.4
and 7.5%, respectively, intensive glycemic therapy was
discontinued because 5.0% of the patients in the intensive
therapy group, compared with 4.0% of those in the stan-
dard therapy group, had died. The cause of excess mor-
tality during intensive glycemic therapy in the ACCORD
study is not known and likely will not be known with
certainty (7). It could have been chance; excess mortality
during intensive glycemic therapy was not observed in the
ADVANCE trial, although there was less glycemic separa-
tion between the groups (median A1C levels of 6.4 and
7.0%) (8). It could have been the result of a nonglycemic
effect of the intensive therapy regimen (e.g., an adverse
effect of one or more of the drugs, weight gain, or
something else), although none was apparent. Nonethe-
less, the most plausible cause of excess mortality during
intensive therapy in the ACCORD study is iatrogenic
hypoglycemia: 1) Median glycemia (A1C) was intention-
ally and demonstrably lower in the intensive glycemic
therapy group. 2) Lower A1C levels are known to be
associated with a higher frequency of hypoglycemia in
type 2 diabetes (7,8,18). Indeed, the prevalence of severe
hypoglycemia was more than threefold higher in the
intensive therapy group in the ACCORD study (7). 3)
Hypoglycemia can be fatal in type 2 diabetes (13,17). That
includes sudden, presumably cardiac arrhythmic death
(13). 4) More patients died in the intensive glycemic
therapy group (7).
Physiology of glucose counterregulation
Hypoglycemia and the brain. Glucose is an obligate
oxidative fuel for the brain under physiological conditions
(1). The brain accounts for 50% of whole-body glucose
utilization. The brain can oxidize alternative fuels, such as
ketones, if their circulating levels rise high enough to enter
the brain in quantity, but that is seldom the case. Because
it cannot synthesize glucose, utilize physiological levels of
circulating nonglucose fuels effectively, or store more than
a few minutes supply of glucose as glycogen, the brain
requires a virtually continuous supply of glucose from
circulation. Since facilitated blood-to-brain glucose trans-
port is a direct function of the arterial plasma glucose
concentration, that supply requires maintenance of plasma
glucose concentration. At some level of hypoglycemia
(perhaps 50–55 mg/dl [2.8–3.1 mmol/l] since symptoms
normally occur at that level [19–21]), blood-to-brain glu-
cose transport becomes limiting to brain glucose metabo-
lism and, therefore, function.
Clinical manifestations of hypoglycemia. The symp-
toms and signs of hypoglycemia are not speciﬁc (1,19,20).
Thus, clinical hypoglycemia is most convincingly docu-
mented by Whipple’s triad: symptoms, signs, or both
consistent with hypoglycemia, a low measured plasma
glucose concentration, and resolution of those symptoms
and signs after the plasma glucose concentration is raised.
Symptoms of hypoglycemia (19) are categorized as
neuroglycopenic (those that are the direct result of brain
glucose deprivation per se) and neurogenic (or auto-
nomic), those that are largely the result of the perception
of physiological changes caused by the sympathoadrenal
(largely the sympathetic neural) (20) discharge triggered by
hypoglycemia. Neuroglycopenic manifestations include cog-
nitive impairments, behavioral changes and psychomotor
abnormalities, and, at lower plasma glucose concentrations,
seizure and coma. Adrenergic neurogenic symptoms include
palpitations, tremor, and anxiety/arousal (19). Cholinergic
neurogenic symptoms include sweating, hunger, and pares-
thesias (19). Central, as well as peripheral, mechanisms may
be involved in the generation of some symptoms such as
hunger (1). Awareness of hypoglycemia is largely the result
of the perception of neurogenic symptoms (19). Pallor and
diaphoresis (the result of adrenergic cutaneous vasocon-
striction and cholinergic stimulation of sweat glands,
respectively) are common signs of hypoglycemia (1).
Neuroglycopenic manifestations are often observable.
Maintenance of systemic glucose balance. Falling
plasma glucose concentrations elicit a sequence of re-
sponses (Table 1) that normally prevent or rapidly correct
hypoglycemia (Fig. 1) (1,21). Because obligatory glucose
utilization by the brain is ﬁxed and exogenous glucose
delivery from food is intermittent, systemic glucose bal-
ance is maintained and hypoglycemia (as well as hyper-
glycemia) is prevented by dynamic regulation of
endogenous glucose production by the liver (and the
kidneys) and of glucose utilization by nonneural tissues
such as muscle.
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glucose concentrations include 1) a decrease in insulin
secretion, 2) an increase in glucagon secretion, and,
absent the latter, an increase in epinephrine secretion
(Table 1, Fig. 1) (1,21). The behavioral defense is the
ingestion of carbohydrates prompted by awareness of
hypoglycemia (Table 1) (Fig. 1) (1,21). The ﬁrst physiolog-
ical defense against hypoglycemia is a decrease in pancre-
atic islet -cell insulin secretion. That occurs as plasma
glucose concentrations decline within the physiological
range (Table 1) and increases hepatic (and renal) glucose
production with virtual cessation of glucose utilization by
insulin-sensitive nonneural tissues (Fig. 1). The second
physiological defense is an increase in pancreatic islet
-cell glucagon secretion. That occurs as plasma glucose
concentrations fall just below the physiological range
(Table 1) and increases hepatic glucose production
(largely by stimulating glycogenolysis) (Fig. 1). Increased
glucagon secretion is signaled by a decrease in intraislet
insulin, perhaps among other -cell secretory products, in
TABLE 1
Physiologic responses to decreasing plasma glucose concentrations
Response
Glycemic threshold
(mg/dl mmol/l)* Physiologic effects
Role in prevention or correction of hypoglycemia
(glucose counterregulation)
2 Insulin 80–85 4.4–4.7 1Ra (2Rd)†
Primary glucose regulatory factor, ﬁrst defense
against hypoglycemia
1 Glucagon 65–70 3.6–3.9 1Ra
Primary glucose counterregulatory factor, second
defense against hypoglycemia
1 Epinephrine 65–70 3.6–3.9 1Ra, 2Rd
Involved, critical when glucagon is deﬁcient, third
defense against hypoglycemia
1 Cortisol and growth hormone 65–70 3.6–3.9 1Ra, 2Rd Involved, not critical
Symptoms 50–55 2.8–3.1 1Exogenous glucose Prompt behavioral defense (food ingestion)
2 Cognition 50 2.8 — (Compromises behavioral defense)
*Arterialized venous, not venous, plasma glucose concentrations.†Ra, rate of glucose appearance, glucose production by the liver and
kidneys; Rd, rate of glucose disappearance, glucose utilization by insulin-sensitive tissues such as skeletal muscle (no direct effect on central
nervous system glucose utilization). This table was prepared initially for Cryer PE: Glucose homeostasis and hypoglycemia. In Williams
Textbook of Endocrinology, 11
th Edition. Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, Eds. Saunders, Philadelphia, 2008, p.
1503–1533.
FIG. 1. Physiological and behavioral defenses against hypoglycemia in humans. ACh, acetylcholine; NE, norepinephrine; PNS, parasympathetic
nervous system; SNS, sympathetic nervous system. From Cryer PE: Mechanisms of sympathoadrenal failure and hypoglycemia in diabetes. J Clin
Invest 116:14701–473, 2006. © 2006, American Society for Clinical Investigation. All rights reserved.
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The third physiological defense, which becomes critical
when glucagon secretion is deﬁcient, is an increase in
adrenomedullary epinephrine secretion. That, too, occurs
as plasma glucose concentrations fall just below the
physiological range (Table 1) and raises plasma glucose
concentrations through an array of mechanisms (Fig. 1).
Those include direct stimulation of hepatic (and renal)
glucose production, limitation of glucose clearance by
insulin-sensitive tissues, mobilization of gluconeogenic
substrates such as lactate and amino acids from muscle
and glycerol from fat, and limitation of insulin secretion
(1,22). Unlike insulin and glucagon secretion, which are
regulated primarily by changes in glucose concentrations
within the pancreatic islets and only secondarily by central
nervous system–mediated autonomic inputs, sympathoad-
renal activity, including epinephrine secretion, is regulated
within the central nervous system (1,21).
If these physiological defenses fail to abort developing
hypoglycemia, lower plasma glucose concentrations cause
a more intense sympathoadrenal response that causes
neurogenic symptoms (Fig. 1) (1,21). Those, in turn, lead
to awareness of hypoglycemia that prompts the behavioral
defense: the ingestion of carbohydrates (1,21). All of these
defenses against developing hypoglycemia, not just insulin
secretion, are typically compromised in people with type 1
diabetes and advanced (i.e., absolutely endogenous insulin
deﬁcient) type 2 diabetes.
Pathophysiology of glucose counterregulation in
diabetes
Insulin excess and compromised defenses. While
insulin excess of sufﬁcient magnitude can cause hypo-
glycemia, iatrogenic hypoglycemia in people with diabe-
tes is typically the result of the interplay of relative or
absolute therapeutic hyperinsulinemia and compro-
mised physiological and behavioral defenses against
falling plasma glucose concentrations (1,23,24). Be-
cause of their pharmacokinetic imperfections, insulin
secretagogues or insulin result in episodes of hyperin-
sulinemia and falling plasma glucose concentrations. It
is the integrity of the defenses against falling plasma
glucose concentrations that determines whether those
episodes result in clinical hypoglycemia.
Defective glucose counterregulation and hypoglyce-
mia unawareness. In fully developed (i.e., C-peptide
negative) type 1 diabetes, circulating insulin concentra-
tions do not decrease as plasma glucose concentrations
decline in response to therapeutic (exogenous) hyperinsu-
linemia (1,23). That is the result of -cell failure, which
also causes loss of the -cell glucagon secretory response
(22). Thus, both the ﬁrst and the second physiological
defenses against hypoglycemia are lost. In that setting, an
attenuated increase in adrenomedullary epinephrine se-
cretion, the third physiological defense, causes the clinical
syndrome of defective glucose counterregulation (1,23),
which is associated with a 25-fold (25) or greater (26)
increased risk of severe iatrogenic hypoglycemia. Further-
more, the attenuated epinephrine response is a marker for
an attenuated sympathoadrenal, including sympathetic
neural, response, which is largely responsible for the
development of the clinical syndrome of hypoglycemia
unawareness (or impaired awareness of hypoglycemia
since there is a spectrum ranging from normal to reduced
to absent awareness) (1,23,27). Hypoglycemia unaware-
ness is associated with a sixfold increased risk of severe
iatrogenic hypoglycemia (27).
Albeit with different time courses, the pathophysiology
of glucose counterregulation is the same in type 1 diabetes
and advanced (i.e., absolutely endogenous insulin deﬁ-
cient) type 2 diabetes (1,23,24). Because absolute -cell
failure (which causes loss of both the insulin and the
glucagon responses) occurs rapidly in type 1 diabetes but
slowly in type 2 diabetes, the syndromes of defective
glucose counterregulation and hypoglycemia unawareness
develop early in type 1 diabetes but later in type 2 diabetes.
That explains why iatrogenic hypoglycemia becomes pro-
gressively more frequent and limiting to glycemic control
as patients approach the insulin-deﬁcient end of the spec-
trum of type 2 diabetes, as discussed earlier.
Hypoglycemia-associated autonomic failure in dia-
betes. The concept of hypoglycemia-associated auto-
nomic failure (HAAF) in diabetes (Fig. 2) posits that
recent antecedent hypoglycemia (1,8,9), as well as prior
exercise (28) or sleep (29), causes both defective glucose
counterregulation (by reducing increments in epinephrine
in the setting of absent decrements in insulin and absent
increments in glucagon during subsequent hypoglycemia)
and hypoglycemia unawareness (by reducing sympatho-
adrenal and the resulting neurogenic symptom responses
during subsequent hypoglycemia) and, therefore, a vicious
cycle of recurrent iatrogenic hypoglycemia. Perhaps the
most compelling support for the concept of HAAF is the
ﬁnding, in three independent laboratories (30–32), that as
little as 2–3 weeks of scrupulous avoidance of hypoglyce-
mia reverses hypoglycemia unawareness and improves the
attenuated epinephrine component of defective glucose
counterregulation in most affected patients. While HAAF is
largely a functional, dynamic disorder that can be induced
and reversed, there may also be a structural (neuro-
pathic) contribution to the attenuated sympathoadrenal
response (1).
Diverse causes of HAAF in diabetes. There are cur-
rently three recognized causes of HAAF: recent anteced-
ent hypoglycemia (23,24), prior exercise (28), and sleep
(29). Each of these inciting events causes an attenuated
sympathoadrenal response to subsequent falling plasma
glucose concentrations, the key feature of HAAF (i.e.,
sympathoadrenal failure associated with the development
of iatrogenic hypoglycemia in people with diabetes).
Hypoglycemia-Associated Autonomic Failure
Antecedent
Exercise
Sleep
Hypoglycemia
Unawareness
Antecedent Hypoglycemia
Insulin Deficient Diabetes
Reduced Sympathoadrenal
Responses to Hypoglycemia
Recurrent Hypoglycemia
Defective Glucose
Counterregulation
(Imperfect Insulin Replacement) 
(No    Insulin, No    Glucagon)
Reduced Sympathetic
Neural Responses
Reduced Epinephrine
Responses
FIG. 2. Schematic diagram of HAAF in diabetes. Modiﬁed from Cryer
PE: Diverse causes of hypoglycemia-associated autonomic failure in
diabetes. N Engl J Med 350:22722–279, 2004. © 2004 Massachusetts
Medical Society. All rights reserved.
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HAAF (1,23,24) led to the concept. Exercise-related HAAF
is exempliﬁed by late postexercise hypoglycemia that
typically occurs 6–15 h after strenuous exercise and is
often nocturnal (1,33,34). It is attributable to an attenuated
sympathoadrenal response to falling plasma glucose con-
centrations (35). Sleep-related HAAF (1,29) is the result of
a further attenuated sympathoadrenal response to falling
plasma glucose concentrations during sleep. Sleeping pa-
tients have both reduced epinephrine responses and re-
duced arousal from sleep.
Mechanisms of HAAF in diabetes. Loss of decrements
in insulin secretion and of increments in glucagon secre-
tion as plasma glucose concentrations fall in response to
therapeutic hyperinsulinemia, prerequisites for HAAF
in type 1 diabetes and advanced type 2 diabetes (1,23,24),
are the result of -cell failure (Fig. 3) (1,22). Since low
glucose concentrations cause decreased insulin and in-
creased glucagon secretion from the transplanted human
and denervated dog pancreas (as well as from the perfused
pancreas and perifused islets), innervation is not required.
Therefore, loss of the glucagon response lies at the level of
the diseased islets.
In the setting of absent insulin and glucagon responses,
an attenuated sympathoadrenal response to falling plasma
glucose concentrations caused by therapeutic hyperinsu-
linemia causes both defective glucose counterregulation
and hypoglycemia unawareness (1,23,24). The mechanism
of the attenuated sympathoadrenal response is not known,
but it must lie at the level of the brain (or the afferent or
efferent components of the sympathoadrenal system) (Fig.
3). Discussion of the various theories of the pathogenesis
of this key feature of HAAF (1,36–39) (the systemic
mediator, brain fuel transport, and brain metabolism hy-
potheses) is beyond the scope of this perspective. While
much of the neuroscience research into this issue has
focused on the hypothalamus (37), recent translational
research has raised the possibility that a complex cerebral
network normally regulates the hypothalamic (and thus
the sympathoadrenal) response to falling plasma glucose
concentrations (38,39) and that an inhibitory signal medi-
ated through the thalamus might be involved in the patho-
genesis of HAAF (Fig. 3) (39). Clearly, much remains to be
learned about the mechanism of HAAF in diabetes.
Risk factors for hypoglycemia in diabetes
Absolute or relative insulin excess. The conventional
risk factors for hypoglycemia in diabetes (Table 2) are
based on the premise that absolute or relative therapeutic
insulin excess is the sole determinant of risk (1,40).
Absolute therapeutic insulin excess occurs when insulin
secretagogue or insulin doses are excessive, ill-timed, or of
the wrong type or when insulin clearance is decreased, as
in renal failure. Relative therapeutic insulin excess occurs
when exogenous glucose delivery is decreased (as follow-
ing missed or low carbohydrate meals and during the
overnight fast), when glucose utilization is increased (as
during and shortly after exercise), when endogenous glu-
cose production is decreased (as following alcohol inges-
tion), and when sensitivity to insulin is increased (as in the
middle of the night or following weight loss, improved
ﬁtness or improved glycemic control). People with diabe-
tes and their caregivers must consider each of these when
hypoglycemia is a problem. However, they explain only a
minority of episodes of iatrogenic hypoglycemia.
Compromised defenses against hypoglycemia. The
risk factors indicative of HAAF (Table 2) include the
degree of endogenous insulin deﬁciency (1,2,41); a history
of severe hypoglycemia, hypoglycemia unawareness, or
both as well as recent antecedent hypoglycemia, prior
exercise, or sleep (1,2,42); and lower mean glycemia
(1,7,8,18,41,42). The degree of endogenous insulin deﬁ-
ciency determines the extent to which insulin levels will
not decrease and glucagon levels will not increase as
plasma glucose concentrations fall in response to thera-
peutic hyperinsulinemia. A history of severe hypoglycemia
indicates (and that of hypoglycemia unawareness implies)
recent antecedent hypoglycemia, which, like prior exer-
cise and sleep, causes attenuated sympathoadrenal and
symptomatic responses to subsequent hypoglycemia, the
key feature of HAAF. Studies with a control group treated
to higher mean glycemia consistently document higher
rates of hypoglycemia in the group treated to lower mean
glycemia (2,7,8,18). The latter does not mean that one
cannot both improve glycemic control and reduce the risk
of hypoglycemia in individual patients (40).
Deﬁnition and classiﬁcation of hypoglycemia. The
American Diabetes Association Workgroup on Hypoglyce-
Attenuated 
Sympathoadrenal
Activity
+
No   Insulin + No   Glucagon
Hippocampus
Brain Stem
Amygdala
Glucose
Dorsal Midline
Thalamus
Hypothalamus
Orbital
Prefrontal
Cortex
Medial Prefrontal
Cortex
Pancreatic Islets
β-Cells           Insulin
α-Cells          Glucagon
X
X
X
FIG. 3. Pancreatic islet and hypothalamic and cerebral network mech-
anisms of HAAF in diabetes.
TABLE 2
Risk factors for hypoglycemia in diabetes
Absolute or relative therapeutic insulin excess
1. Insulin or insulin secretagogue doses are excessive, ill-timed,
or of the wrong type
2. Exogenous glucose delivery is decreased (e.g., following
missed meals and during the overnight fast)
3. Glucose utilization is increased (e.g., during and shortly after
exercise)
4. Endogenous glucose production is decreased (e.g., following
alcohol ingestion)
5. Sensitivity to insulin is increased (e.g., in the middle of the
night and following weight loss, improved ﬁtness or
improved glycemic control)
6. Insulin clearance is decreased (e.g., with renal failure)
HAAF
1. Absolute endogenous insulin deﬁciency
2. A history of severe hypoglycemia, hypoglycemia
unawareness, or both as well as recent antecedent
hypoglycemia, prior exercise, and sleep
3. Aggressive glycemic therapy per se (lower A1C levels, lower
glycemic goals)
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of abnormally low plasma glucose concentration that
expose the individual to potential harm.” The American
Diabetes Association Workgroup recommended that peo-
ple with drug-treated diabetes (implicitly those treated
with an insulin secretagogue or insulin) become con-
cerned about the possibility of developing hypoglycemia at
a plasma glucose concentration of 70 mg/dl (3.9 mmol/l)
(43). Within the error of self-blood glucose monitoring (or
continuous glucose sensing), that conservative alert level
approximates the lower limit of the physiological postab-
sorptive plasma glucose concentration range and the
glycemic thresholds for activation of physiological glucose
counterregulatory systems and is low enough to reduce
glycemic defenses against subsequent hypoglycemia in
nondiabetic individuals. The recommended alert value
does not mean that people with diabetes should always
treat for hypoglycemia at an estimated plasma glucose
concentration of 70 mg/dl. Rather, it indicates that they
should consider actions ranging from repeating the mea-
surement in the near term through behavioral changes
such as avoiding exercise or driving without treatment to
carbohydrate ingestion and subsequent regimen adjust-
ments. The intent of the use of the alert value is to prevent
clinical hypoglycemia and not to estimate the frequency of
clinically important hypoglycemia. The Workgroup also
suggested the following classiﬁcation of hypoglycemia in
diabetes: 1) severe hypoglycemia, 2) documented symp-
tomatic hypoglycemia, 3) asymptomatic hypoglycemia, 4)
probable symptomatic hypoglycemia, and 5) relative hy-
poglycemia. Those require 1) an episode requiring the
assistance of another person, 2) symptoms and a plasma
glucose concentration 70 mg/dl, 3) a plasma glucose
concentration 70 mg/dl without symptoms, 4) symptoms
attributed to hypoglycemia without a plasma glucose
measurement, and 5) symptoms attributed to hypoglyce-
mia with a plasma glucose concentration 70 mg/dl but
falling toward that level, respectively.
Hypoglycemia risk factor reduction. It is, of course,
preferable to prevent rather than treat iatrogenic hypogly-
cemia. The prevention of hypoglycemia requires the prac-
tice of hypoglycemia risk factor reduction (1,40). That
involves 1) acknowledging and addressing the problem, 2)
applying the principles of intensive glycemic therapy (di-
abetes self-management based on patient education and
empowerment, frequent self blood glucose monitoring
[and in some instances continuous glucose sensing], ap-
propriate and ﬂexible insulin [and other drug] regimens
including use of insulin analogues, individualized glycemic
goals, and ongoing professional guidance and support), 3)
considering the conventional risk factors and adjusting the
regimen appropriately, and 4) considering the risk factors
indicative of HAAF in diabetes. With respect to the latter,
a history of severe hypoglycemia should prompt consider-
ation of a substantial change in the treatment regimen and
a history of hypoglycemia unawareness should prompt
consideration of a 2- to 3-week period of scrupulous
avoidance of hypoglycemia with the anticipation that
awareness of hypoglycemia will return (30–32). Minimiz-
ing the risk of hypoglycemia while maintaining meaningful
glycemic control is a challenge for people with diabetes
and their caregivers, which is addressed in detail sepa-
rately (44).
Perspective on hypoglycemia in diabetes. Diabetes is a
common chronic disease. Its human and economic costs
are large and, despite therapeutic advances, growing be-
cause of the increasing prevalence of diabetes. Glycemic
control is only one aspect of the management of diabe-
tes. It is now possible to drive plasma LDL cholesterol
concentrations to subphysiological levels and to nor-
malize blood pressure pharmacologically, usually with-
out major side effects, in most people with diabetes.
Weight reduction and smoking cessation are more chal-
lenging, but worthy, goals in obese patients or those
who smoke. However, it is not possible to maintain
euglycemia over a lifetime of diabetes because of the
barrier of hypoglycemia.
Nonetheless, people with diabetes and their caregivers
should keep the problem of iatrogenic hypoglycemia in
perspective. The principle of the glycemic management of
diabetes is that maintenance of glycemia as close to the
nondiabetic range as can be accomplished safely over time
is generally in the patient’s best interests. The extent to
which that goal can be met is a function of many factors,
including the type of diabetes and the stage in the progres-
sion of the disease in the individual patient. Early in the
course of type 2 diabetes, by far the most common type of
diabetes, hyperglycemia may respond to lifestyle changes,
speciﬁcally weight loss, or to plasma glucose–lowering
drugs that should not, and probably do not, cause hypo-
glycemia. In theory, when such drugs are effective in the
absence of side effects, there is no reason not to accelerate
their dosing until euglycemia is achieved. Over time,
however, as people with type 2 diabetes become progres-
sively more insulin deﬁcient, these drugs, even in combi-
nation, fail to maintain glycemic control. Insulin
secretagogues are also effective early in type 2 diabetes,
but they can cause hyperinsulinemia and therefore intro-
duce the risk of hypoglycemia. Euglycemia is not an
appropriate goal during therapy with an insulin secreta-
gogue or with insulin in people with type 2 diabetes.
Nonetheless, as discussed earlier, the frequency of hypo-
glycemia is relatively low (at least with current glycemic
goals that are above the euglycemic range) during treat-
ment with an insulin secretagogue, or even with insulin,
early in type 2 diabetes (9) when defenses against hypo-
glycemia are intact. Thus, over much of the course of the
most common type of diabetes it is possible to achieve a
meaningful degree of glycemic control with no risk or
relatively low risk of hypoglycemia. The challenge is
greater in people with advanced type 2 diabetes or type 1
diabetes because of compromised defenses against hy-
poglycemia. In such patients, therapy with insulin is
demonstrably effective, but it is not demonstrably safe.
Nonetheless, concerns about hypoglycemia should not
be used as an excuse for poor glycemic control by
patients or their caregivers. Both should strive to
achieve and maintain the greatest degree of glycemic
control that can be accomplished safely in a given
person with diabetes at a given stage of the progression
of his or her diabetes. It should be recalled that the
relationship between mean glycemia and microvascular
complications is curvilinear (2,5). While near euglyce-
mia is desirable, some degree of long-term glycemic
control puts the patient at lower risk than little or no
glycemic control (5).
Diabetes will someday be cured and prevented. Pending
that, elimination of hypoglycemia from the lives of people
with diabetes will likely be accomplished by new treat-
ment methods that provide plasma glucose–regulated in-
sulin replacement or secretion. In the meantime,
innovative research is needed if we are to improve the
PERSPECTIVES IN DIABETES
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barrier of hypoglycemia.
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